Absolute event rates and RR of new antiplatelet compared with clopidogrel in LOF and non-LOF of genetic substudies
| Substudy acronym . | Comparison . | Outcome . | New antiplatelet vs clopidogrel event rates for the LOF subgroup . | New antiplatelet vs clopidogrel event rates for the non-LOF subgroup . | RR + 95% CI in LOF subgroup . | RR + 95% CI in non-LOF subgroup . |
|---|---|---|---|---|---|---|
| TIMI TRITON 38*15,94 | Prasugrel vs clopidogrel | MACE | 34/407(8.5%) vs 46/395 (12.1%) | 99/1048(9.8%) vs 83/1064 (8.6%) | 0.57 (0.39-0.83) | 0.98 (0.80-1.20) |
| TIMI major + minor bleeding | 17/405(4.5%) vs 11/393 (2.9%) | 38/1047 (3.8%) vs 30/1061 (3.0%) | 1.60 (0.8-3.1) | 1.38 (1.00-1.93) | ||
| PLATO95 | Ticagrelor vs clopidogrel | MACE | 115/1384(8.3%) vs 149/1388(10.7%) | 296/3554(8.3%) vs 332/3516 (9.45) | 0.77 (0.60-0.99) | 0.86 (0.74-1.01) |
| Major bleeding | 149/1380 (10.8%) vs 143/1380 (10.4%) | 331/3547(9.3%) vs 340/3506(9.7%) | 1.04 (0.82-1.30) | 0.96 (0.83-1.12) |
| Substudy acronym . | Comparison . | Outcome . | New antiplatelet vs clopidogrel event rates for the LOF subgroup . | New antiplatelet vs clopidogrel event rates for the non-LOF subgroup . | RR + 95% CI in LOF subgroup . | RR + 95% CI in non-LOF subgroup . |
|---|---|---|---|---|---|---|
| TIMI TRITON 38*15,94 | Prasugrel vs clopidogrel | MACE | 34/407(8.5%) vs 46/395 (12.1%) | 99/1048(9.8%) vs 83/1064 (8.6%) | 0.57 (0.39-0.83) | 0.98 (0.80-1.20) |
| TIMI major + minor bleeding | 17/405(4.5%) vs 11/393 (2.9%) | 38/1047 (3.8%) vs 30/1061 (3.0%) | 1.60 (0.8-3.1) | 1.38 (1.00-1.93) | ||
| PLATO95 | Ticagrelor vs clopidogrel | MACE | 115/1384(8.3%) vs 149/1388(10.7%) | 296/3554(8.3%) vs 332/3516 (9.45) | 0.77 (0.60-0.99) | 0.86 (0.74-1.01) |
| Major bleeding | 149/1380 (10.8%) vs 143/1380 (10.4%) | 331/3547(9.3%) vs 340/3506(9.7%) | 1.04 (0.82-1.30) | 0.96 (0.83-1.12) |
Genetic substudies were reported separately for prasugrel and clopidogrel. The relative risk quoted for TRITON TIMI 38 substudy is that reported by Sorich et al96 and was estimated by applying the relative risk from the genetic substudy to the overall results of TIMI TRITON 38; 95% CI was estimated using Monte Carlo simulation.